Ignite Creation Date:
2025-12-24 @ 11:16 PM
Ignite Modification Date:
2026-04-22 @ 3:08 AM
Study NCT ID:
NCT02289456
Status:
COMPLETED
Last Update Posted:
2018-12-07
First Post:
2014-11-10
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2
Sponsor:
Celgene
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-04-28
Start Date Type:
ACTUAL
Primary Completion Date:
2017-02-22
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-02-22
Completion Date Type:
ACTUAL
First Submit Date:
2014-11-10
First Submit QC Date:
None
Study First Post Date:
2014-11-13
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-02-22
Results First Submit QC Date:
None
Results First Post Date:
2018-04-24
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-12-04
Last Update Post Date:
2018-12-07
Last Update Post Date Type:
ACTUAL